[go: up one dir, main page]

CR8377A - Derivados de acidos fenoxiaceticos utiles como agonistas dobles de receptor activado por proliferador de peroxisoma - Google Patents

Derivados de acidos fenoxiaceticos utiles como agonistas dobles de receptor activado por proliferador de peroxisoma

Info

Publication number
CR8377A
CR8377A CR8377A CR8377A CR8377A CR 8377 A CR8377 A CR 8377A CR 8377 A CR8377 A CR 8377A CR 8377 A CR8377 A CR 8377A CR 8377 A CR8377 A CR 8377A
Authority
CR
Costa Rica
Prior art keywords
proofisador
peroxisoma
derivatives
useful
phenoxyacetic acids
Prior art date
Application number
CR8377A
Other languages
English (en)
Inventor
Kuo Gee-Hong
Shen Lan
Wang Aihua
Zhang Yan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR8377A publication Critical patent/CR8377A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invencion se refiere a acidos fenoxiaceticos y analogos de la formula (I), composiciones que los contienen, y metodos para usarlos como moduladores de PPAR para tratar o inhibir la progresion de, por ejemplo, dislipidemia.
CR8377A 2003-10-31 2006-05-02 Derivados de acidos fenoxiaceticos utiles como agonistas dobles de receptor activado por proliferador de peroxisoma CR8377A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51656103P 2003-10-31 2003-10-31

Publications (1)

Publication Number Publication Date
CR8377A true CR8377A (es) 2008-11-24

Family

ID=34549548

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8377A CR8377A (es) 2003-10-31 2006-05-02 Derivados de acidos fenoxiaceticos utiles como agonistas dobles de receptor activado por proliferador de peroxisoma

Country Status (21)

Country Link
US (3) US7015329B2 (es)
EP (1) EP1684752B1 (es)
JP (1) JP2007527416A (es)
KR (1) KR20060109925A (es)
CN (1) CN1897939A (es)
AR (1) AR046311A1 (es)
AT (1) ATE362367T1 (es)
AU (1) AU2004285530A1 (es)
BR (1) BRPI0416106A (es)
CA (1) CA2544317A1 (es)
CR (1) CR8377A (es)
DE (1) DE602004006529T2 (es)
EA (1) EA009804B1 (es)
EC (1) ECSP066536A (es)
ES (1) ES2287786T3 (es)
IL (1) IL175310A0 (es)
NO (1) NO20062511L (es)
TW (1) TW200528438A (es)
UA (1) UA84035C2 (es)
WO (1) WO2005041959A1 (es)
ZA (1) ZA200604420B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA87467C2 (en) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US7015329B2 (en) * 2003-10-31 2006-03-21 Janssen Pharmaceutica N. V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US20080045580A1 (en) * 2004-10-11 2008-02-21 Dr Reddy's Laboratories Limited Novel Isoxazole Compounds Having Ppar Agonist Activity
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
UY30288A1 (es) * 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
AU2007292874B2 (en) 2006-09-08 2013-11-21 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced liver disease
KR20090066289A (ko) 2006-09-08 2009-06-23 로드아일랜드하스피틀 알코올 유발성 뇌 질환의 치료, 예방 및 역행
AU2008240158B2 (en) 2007-04-11 2014-07-10 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2310371B1 (fr) 2008-05-26 2013-05-15 Genfit Composés agonistes ppar, préparation et utilisations pour le traitement du diabète et/ou des dyslipidémies
CN104086528A (zh) 2010-07-15 2014-10-08 拜耳知识产权有限责任公司 作为杀虫剂的新杂环化合物
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション PPARδアゴニストの胎児再プログラミング用途
CN103270029B (zh) 2010-10-22 2016-01-20 拜耳知识产权有限责任公司 作为农药的杂环化合物
CN104583218B (zh) 2012-04-26 2018-04-24 百时美施贵宝公司 作为蛋白酶活化受体4(par4)抑制剂用于治疗血小板聚集的咪唑并噻二唑和咪唑并吡嗪的衍生物
JP2015516983A (ja) 2012-04-26 2015-06-18 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Par4アゴニストペプチド
KR102750722B1 (ko) * 2022-03-16 2025-01-09 재단법인 대구경북첨단의료산업진흥재단 싸이아다이아졸 화합물 및 이를 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물
WO2024153134A1 (zh) * 2023-01-18 2024-07-25 哈尔滨三联药业股份有限公司 五元杂环类化合物及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
US6242493B1 (en) 1998-03-13 2001-06-05 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
AU4167099A (en) 1998-06-19 2000-01-05 Nissan Chemical Industries Ltd. Heterocyclic compounds as hypoglycemic agents
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
DE60027420T2 (de) 1999-04-28 2006-11-16 Aventis Pharma Deutschland Gmbh Tri-aryl-säurederivate als ppar rezeptor liganden
DK1177187T3 (da) 1999-04-28 2007-10-15 Sanofi Aventis Deutschland Diarylsyrederivater som PPAR-receptorligander
CA2382966A1 (en) * 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
ATE542805T1 (de) * 2000-08-11 2012-02-15 Nippon Chemiphar Co Ppar-delta aktivatoren
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7714004B2 (en) * 2002-12-20 2010-05-11 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US7015329B2 (en) * 2003-10-31 2006-03-21 Janssen Pharmaceutica N. V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs

Also Published As

Publication number Publication date
ZA200604420B (en) 2007-10-31
NO20062511L (no) 2006-07-27
EP1684752B1 (en) 2007-05-16
BRPI0416106A (pt) 2007-01-02
US20050096362A1 (en) 2005-05-05
EA009804B1 (ru) 2008-04-28
DE602004006529T2 (de) 2008-01-31
EA200600878A1 (ru) 2006-10-27
CN1897939A (zh) 2007-01-17
ATE362367T1 (de) 2007-06-15
IL175310A0 (en) 2006-09-05
US20090131489A1 (en) 2009-05-21
US7498351B2 (en) 2009-03-03
KR20060109925A (ko) 2006-10-23
ES2287786T3 (es) 2007-12-16
UA84035C2 (ru) 2008-09-10
JP2007527416A (ja) 2007-09-27
AR046311A1 (es) 2005-11-30
US20060074246A1 (en) 2006-04-06
ECSP066536A (es) 2006-12-20
WO2005041959A1 (en) 2005-05-12
US7015329B2 (en) 2006-03-21
CA2544317A1 (en) 2005-05-12
DE602004006529D1 (de) 2007-06-28
EP1684752A1 (en) 2006-08-02
AU2004285530A1 (en) 2005-05-12
TW200528438A (en) 2005-09-01

Similar Documents

Publication Publication Date Title
CR8377A (es) Derivados de acidos fenoxiaceticos utiles como agonistas dobles de receptor activado por proliferador de peroxisoma
ECSP088590A (es) Derivados de aminoácido multicíclicos y sus métodos de uso
CR10554A (es) Agonistas de ep2
AR053334A1 (es) Pirazolilcarboxanilidas
ECSP066434A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
PA8693101A1 (es) Compuestos de isoindol-imida y composiciones que los incluyen y mètodos para su uso
CR9786A (es) Compuestos de bencimidazol-tiofeno
ECSP077319A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos, y analogos de los mismos
ECSP11011347A (es) Nicotinamida sustituida como moduladores KCNQ2/3
CR7566A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
CR9589A (es) Agonistas del receptor de niacina, composiciones que contienen tales compuestos y procedimientos para tratamiento
CR9814A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
UY30627A1 (es) Inhibidores de metaloproteasas derivados de heterociclos
NI200700074A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
BRPI0518203A2 (pt) mÉtodos para preparaÇço de compostos indazol
PA8663501A1 (es) Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
DOP2006000017A (es) Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso
GT200400143A (es) Compuestos
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
ECSP066435A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
NO20073501L (no) Pyrrolidin-2-on derivater for anvendelse som DPI reseptor agonister
DK1554240T3 (da) Substituerede tetraliner og indaner og deres anvendelse
CR8334A (es) Isopentilcarboxanilidas para la lucha contra los microorganismos indeseables